- |||||||||| letrozole / Generic mfg.
Journal: Evidence-based treatments for couples with unexplained infertility: a guideline. (Pubmed Central) - Jul 24, 2020 The treatment of unexplained infertility is by necessity empiric. For most couples, the best initial therapy is a course (typically 3 or 4 cycles) of ovarian stimulation with oral medications and intrauterine insemination (OS-IUI) followed by in vitro fertilization for those unsuccessful with OS-IUI treatments.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, letrozole / Generic mfg., Faslodex (fulvestrant) / AstraZeneca
Clinical, Journal: Two Cases of Stage Ⅳ Occult Breast Cancer (Pubmed Central) - Jul 24, 2020 However, after 6 months, she discontinued the treatment. Our results suggested that effective control could be achieved through systemic therapy and local therapy was not necessary for Stage Ⅳ occult breast cancer.
- |||||||||| Tecentriq (atezolizumab) / Roche
New P1/2 trial, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, MSi-H Companion diagnostic, PARP Companion diagnostic, PD(L)-1 companion diagnostic: AFT-50 EndoMAP: A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) - Jul 23, 2020 P1/2, N=60, Not yet recruiting,
- |||||||||| letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica, tamoxifen / Generic mfg.
[VIRTUAL] Lipid changes during endocrine therapy in breast cancer patients: The results of a 5-year real-world retrospective analysis (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_527; Results For premenopausal BC patients, LDL levels rapidly decreased at 1 year in the tamoxifene (TAM) group compared with baseline (p<0.05), and the decline remained for the following 4 years...For postmenopausal BC patients, there was no statistical difference in the lipid profiles (TG, TC, LDL and HDL) in letrozole (LET), anastrozole (ANA) and exemestane (EXE) group compared with the control group, respectively...Legal entity responsible for the study: West China School of Medicine/West China Hospital, Sichuan University. Funding: Has not received any funding.
- |||||||||| Soltamox (tamoxifen citrate) / Jazz
Enrollment closed, Trial completion date, Trial primary completion date: PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov) - Jul 20, 2020 P2, N=42, Active, not recruiting, Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2020 --> Jul 2021
- |||||||||| NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects (clinicaltrials.gov) - Jul 14, 2020 P1, N=60, Recruiting, Phase classification: P2/3 --> P3 | N=600 --> 926 | Trial completion date: Mar 2026 --> Dec 2025 | Trial primary completion date: Mar 2023 --> Dec 2025 Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2020 --> Jun 2021
- |||||||||| letrozole / Generic mfg.
Enrollment open: Novel Therapy for Poor Responders Management (clinicaltrials.gov) - Jul 7, 2020 P=N/A, N=100, Recruiting, Trial completion date: May 2023 --> Jan 2023 | Trial primary completion date: May 2023 --> Jan 2023 Not yet recruiting --> Recruiting
- |||||||||| Ibrance (palbociclib) / Pfizer
[VIRTUAL] A Tale of Unexplained Pneumotoxicity: The Dangers of Palbociclib (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_3978; An exhaustive laboratory workup was done in order to exclude other causes that may result in diffuse lung injury, including infection, environmental exposure, and malignancy. This should not deter physicians from using palbociclib as a chemotherapeutic agent in patient with advanced stage breast cancer, as the PALOMA-2 trial has shown that combining palbociclib with letrozole can lead to a median progression free survival of thirteen months in patients who are ER-positive and HER2-negative.
- |||||||||| letrozole / Generic mfg., methotrexate / Generic mfg.
Journal: Aromatase inhibitor letrozole: a novel treatment for ectopic pregnancy. (Pubmed Central) - Jul 6, 2020 To our knowledge, this is the first report in the literature on the success of letrozole for the medical treatment of ectopic pregnancy. The promisingly high resolution rate and better safety profile that letrozole has compared with a chemotherapeutic agent such as methotrexate should encourage further studies.
- |||||||||| letrozole / Generic mfg., taselisib (GDC-0032) / Roche
Clinical, P2 data, Journal: Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. (Pubmed Central) - Jul 2, 2020 P2 The promisingly high resolution rate and better safety profile that letrozole has compared with a chemotherapeutic agent such as methotrexate should encourage further studies. The increase in the proportion of patients who achieved an objective response from the addition of taselisib to endocrine therapy in a neoadjuvant setting is consistent with the clinical benefit observed in hormone receptor-positive, HER2-negative, metastatic breast cancer.
- |||||||||| letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica, exemestane / Generic mfg.
Review, Journal: Polyphenolic natural products and natural product-inspired steroidal mimics as aromatase inhibitors. (Pubmed Central) - Jun 29, 2020 Pursuit of this strategy over the last few decades has been largely successful although complications and challenges remain. This review highlights the aromatase activity of natural stilbenes, chalcones, and flavanones and synthetically inspired versions thereof and draws attention to new and under-investigated areas within each class worthy of pursuit.
|